A brave gran battling breast cancer for more than a decade is facing the heart-wrenching prospect of moving hundreds of miles to Scotland for access to a drug that could save her life. Beverley Angell ...

A grandma who has fought breast cancer for more than a decade may be forced to move to Scotland to access a lifesaving drug. Beverley Angell, 68, is having to consider moving 467 miles from London to ...

Beverley Angell, 68, is having to consider moving 467 miles from London to Scotland as the drug she needs - Enhurtu for HER2-low - is not available on the NHS in England. Privately it would cost ...

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

A new drug that helps slow the spread of an incurable type of breast cancer has been approved for use in Britain's state-run ...

The global Breast Cancer Diagnostics Market is valued at USD 19.43 Billion in 2024 and is projected to reach a value of USD ...

Breast cancer remains the most common cancer among women globally, and Germany stands at the forefront of offering advanced and effective treatment options. Through a combination of high medical ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug ...